[November 09, 2012]

SpinalCyte, LLC Profiled in Medical Device Daily

SpinalCyte, LLC, a spinal technology company focused on autologous regrowth of the spinal disc nucleus using human dermal fibroblasts, was profiled in the November 9, 2012 issue of Medical Device Daily in a featured "New Company On The Go" interview. Medical Device Daily, the world's leading med-tech news and information source, is the daily source for world-wide developments in the medical community. SpinalCyte has successfully completed its first round of animal studies with Howard An, M.D. at Rush University in Chicago. Using intermittent hydrostatic pressure, the dermal cells have successfully differentiated into cartilage type cells necessary to regrow the nucleus pulposus.

The nucleus pulposus is a gelatinous material that acts as a cushion or shock absrber to the spinal column. It functions to distribute hydraulic pressure in all directions within each disc under compressive loads. The nucleus pulposus consists of chondrocytes, collagenfibrils, and proteoglycan aggrecans.

"This featured article gives international exposure to our emerging technology," said Pete O'Heeron, Chief Executive Officer. "We feel a cell-based solution for degenerative disc disease is the future treatment of choice and our autologous cell-based solution is a leader in the efforts to find a biologic therapy to regenerate the disc."

SpinalCyte News Release and Feature Article.

About SpinalCyte, LLC

Based in Houston, Texas, SpinalCyte, LLC is a spinal technology company founded in 2007 for the purpose of developing an innovative and autologous solution for nucleus replacement technology using human dermal fibroblasts. The goal of SpinalCyte is to develop a nucleus regrowth technology using autologous dermal cells harvested from the patient. SpinalCyte is currently seeking additional funding for its final animal trials. To date, SpinalCyte has been funded entirely by angel investors.

[ Back To Technology News's Homepage ]